<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased water T2 values indicates the presence of vasogenic <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Decreased apparent diffusion coefficient (<z:chebi fb="49" ids="35181">ADC</z:chebi>) maps reveal ischemic areas displaying cytotoxic <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="49" ids="35181">ADC</z:chebi> and T2 abnormalities spread through the middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) territory up to 24 h after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="3" pm="."><plain>Also, it was found that <z:chebi fb="49" ids="35181">ADC</z:chebi> and T2 contours closely match at 3.5 and 24 h </plain></SENT>
<SENT sid="4" pm="."><plain>Since <z:chebi fb="0" ids="52684">butanediol</z:chebi> reduces vasogenic <z:hpo ids='HP_0000969'>edema</z:hpo> and improves energy status in various models of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, we used these two techniques to investigate putative improvements in cytotoxic and vasogenic <z:hpo ids='HP_0000969'>edema</z:hpo> after permanent MCAO performed on rats </plain></SENT>
<SENT sid="5" pm="."><plain>Rats were given no treatment (n = 8), or a treatment with 25 mmol/kg intraperitoneal (i.p.) <z:chebi fb="0" ids="52684">butanediol</z:chebi> (n = 5), 30 min before and 2.5 h after MCAO </plain></SENT>
<SENT sid="6" pm="."><plain>Quantitative <z:chebi fb="49" ids="35181">ADC</z:chebi> and T2 maps of brain water were obtained, from which the volumes presenting abnormalities were calculated at various time points up to 24 h </plain></SENT>
<SENT sid="7" pm="."><plain>Effects of <z:chebi fb="0" ids="52684">butanediol</z:chebi> on the <z:chebi fb="49" ids="35181">ADC</z:chebi> and T2 values in these areas were determined </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="52684">Butanediol</z:chebi> reduced neither the <z:chebi fb="49" ids="35181">ADC</z:chebi> volume nor the initial <z:chebi fb="49" ids="35181">ADC</z:chebi> decline </plain></SENT>
<SENT sid="9" pm="."><plain>However, it reduced T2 volumes by 32% at 3.5 h and 15% at 24 h (p &lt; 0.05), and reduced T2 increase in the striatum at 3.5 h post-MCAO </plain></SENT>
<SENT sid="10" pm="."><plain>Therefore, our results show for the first time that a pharmacological agent such as <z:chebi fb="0" ids="52684">butanediol</z:chebi> can delay the development of vasogenic <z:hpo ids='HP_0000969'>edema</z:hpo> but does not limit the development of vasogenic <z:hpo ids='HP_0000969'>edema</z:hpo> but does not limit the development of cytotoxic <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="49" ids="35181">ADC</z:chebi> imaging detects areas of severe metabolic disturbance but not moderately ischemic peripheral areas where <z:chebi fb="0" ids="52684">butanediol</z:chebi> is presumed to be more efficacious </plain></SENT>
</text></document>